Overview

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess the efficacy and safety of restarting ruxolitinib after treatment interruption due to loss of response and/or adverse events.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals